Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 145 intravascular ultrasound atherosclerosis burden study in coronary artery disease
2012-004208-37Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of evolocumab in coronary arteriosclerosis, atherosclerosis, sponsored by Amgen. Started Feb 2013; status: completed.
02
Drugs
evolocumab
03
Conditions
coronary arteriosclerosisatherosclerosis
Beyond the preview
Go deeper on 2012-004208-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004208-37.